DVT Prophylaxis for Elderly Patients with CKD Stage 3

Medication Selection and Dosing

The American College of Cardiology recommends enoxaparin 30 mg subcutaneously once daily for DVT prophylaxis in elderly patients with moderate renal impairment, due to its predictable anticoagulation effect and lower risk of heparin-induced thrombocytopenia 1
For patients with CKD stage 3, dose reduction is necessary as renal clearance of enoxaparin is reduced by 31% in moderate renal impairment, with a recommended prophylactic dose of 30 mg subcutaneously once daily 2, 3
Dose adjustment is critical as enoxaparin is associated with a 2-3 fold increased risk of bleeding when administered in standard doses to patients with renal insufficiency 3

The American College of Cardiology recommends continuing DVT prophylaxis for the duration of hospitalization or until fully ambulatory for medical patients, and at least 7-10 days post-procedure for surgical patients 1
Extended prophylaxis beyond hospital discharge is generally not recommended for this patient population unless specific high-risk factors are present 4

Regular assessment of renal function is essential as elderly patients may experience fluctuations in creatinine clearance, and monitoring for signs of bleeding is crucial 5
Although routine anti-Xa monitoring is not required for prophylactic dosing in CKD stage 3, it may be considered if clinical concerns arise about efficacy or safety 3

Advanced age (≥75 years) is an independent risk factor for both thrombosis and bleeding complications, requiring careful balance of risks 6
Concomitant medications that increase bleeding risk (antiplatelets, NSAIDs, SSRIs) should be carefully evaluated and potentially discontinued during prophylaxis 5

For patients at very high bleeding risk, intermittent pneumatic compression devices may be preferred over pharmacological prophylaxis 6